Lomitapide (JUXTAPID)
Microsomal triglyceride transfer protein (MTP) inhibitor
Lomitapide (JUXTAPID)
Forms and strengths
Form: TabletStrength: 5 mg, 10 mg, 20 mg
References
Indication
- Lomitapide is used as an adjunct to a low-fat diet and other lipid-lowering drugs, with or without LDL apheresis, to reduce LDL cholesterol in adults with homozygous familial hypercholesterolemia (HoFH).
- Because of its safety profile, treatment should be limited to physicians experienced in diagnosing and treating familial hypercholesterolemia.
- The effect of lomitapide on cardiovascular illness and death has not been established.
Pregnancy
Contraindicated in pregnancy. Confirm pregnancy status and discuss alternative therapy with the prescriber before dispensing.
- Lomitapide is contraindicated during pregnancy because it may cause fetal harm.
- Lomitapide was teratogenic in rats and ferrets at exposures below the human therapeutic dose, and caused embryo-fetal death in rabbits at higher exposures.
- Before starting treatment, pregnancy should be ruled out in women of childbearing potential and effective contraception started; patients on estrogen-based oral contraceptives should be told that diarrhea or vomiting can reduce contraceptive effectiveness.
- Patients who become pregnant while taking lomitapide should stop the drug immediately and contact their healthcare professional.
Breastfeeding
- It is not known whether lomitapide passes into human breast milk.
- Because lomitapide caused tumours in a 2-year mouse study, a decision should be made whether to discontinue breastfeeding or discontinue lomitapide, taking into account the importance of treatment to the mother.
Geriatrics
- Clinical studies did not include enough patients 65 years of age and older with HoFH to determine whether they respond differently than younger patients.
- Dosing in elderly patients should be cautious, reflecting the greater likelihood of reduced liver, kidney, or heart function and other concurrent medications.
Pediatrics
- Safety and effectiveness in patients under 18 years of age have not been established, so Health Canada has not authorized a pediatric indication.
Dosage & Administration
- The recommended starting dose is 5 mg once daily, taken without food.
- After at least 2 weeks the dose may be increased to 10 mg, then at intervals of at least 4 weeks further increased to 20 mg, 40 mg, and a maximum of 60 mg daily, based on tolerability and LDL-C response.
- Patients should follow a diet supplying less than 20% of calories from fat before and during treatment, since this reduces the frequency and severity of gastrointestinal side effects.
- Daily dietary supplements containing vitamin E and essential fatty acids (linoleic acid, alpha-linolenic acid, EPA, and DHA) are recommended to prevent fat-soluble nutrient deficiency, and should be taken at least 2 hours apart from lomitapide.
- Liver enzymes (ALT and/or AST) should be measured before starting treatment and before each dose increase, then monthly during the first year and every 3 months afterward; dose reduction or discontinuation is required based on the degree of elevation.
- Patients on dialysis for end-stage renal disease should not exceed 40 mg daily; dosing in other forms of renal impairment has not been studied.
- Patients with mild hepatic impairment (Child-Pugh A) should not exceed 40 mg daily; lomitapide is contraindicated in moderate or severe hepatic impairment.
- Capsules should be swallowed whole with a glass of water at least 2 hours after the evening meal, and never opened, crushed, dissolved, or chewed.
- If a dose is missed, take the normal dose the next day at the usual time; contact the healthcare provider before restarting if treatment is interrupted for more than a week.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- There is no specific antidote for lomitapide overdose.
- Overdose should be managed with symptomatic treatment and general supportive care.
- Liver function tests should be monitored after a suspected overdose.
- Because lomitapide is highly bound to blood proteins, hemodialysis is not expected to remove it from the blood.
Common side effects
- Diarrhea is very common.
- Nausea is very common.
- Indigestion (dyspepsia) is common.
- Vomiting is common.
- Abdominal pain is common.
- Abdominal bloating (distension) may occur.
- Constipation may occur.
- Gas (flatulence) may occur.
- Heartburn (gastroesophageal reflux) may occur.
- An urgent need to have a bowel movement may occur.
- Weight loss may occur.
- Fatigue may occur.
- Headache may occur.
- Dizziness may occur.
- Back pain may occur.
- Sore throat (pharyngolaryngeal pain) may occur.
- Nasal congestion may occur.
- Flu-like illness may occur.
- Cold-like symptoms (nasopharyngitis) may occur.
- Fever may occur.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Elevated liver enzymes (ALT and/or AST) are common and usually reversible, but require dose adjustment or discontinuation depending on the degree of elevation.
- Hepatic steatosis (fat accumulation in the liver) occurs in most treated patients, and its long-term consequences, including possible progression to steatohepatitis, fibrosis, or cirrhosis, are unknown.
- Severe diarrhea and dehydration can occur, increasing the risk of low blood pressure and fainting, particularly in older adults or those taking diuretics.
- Chest pain has been reported.
- Angina pectoris (chest pain from reduced blood flow to the heart) has been reported.
- Heart palpitations have been reported.
- A case of myocardial infarction (heart attack) has been reported.
- Hypersensitivity reactions have been reported.
- Gastrointestinal bleeding, including vomiting blood or blood in the stool, has been reported.
- Hair loss (alopecia) has been reported after treatment.
- Seek urgent medical attention for yellowing of the skin or eyes, dark urine, severe abdominal pain, unusual fatigue, chest pain, or signs of severe dehydration.
Use with caution
- Use with caution in patients who consume alcohol, since it can worsen liver injury, including hepatic steatosis; limit to no more than one drink daily.
- Use with caution when combining with other drugs known to cause liver injury, such as isotretinoin, amiodarone, high-dose acetaminophen, methotrexate, tetracyclines, and tamoxifen, and consider more frequent liver monitoring.
- Use with caution in geriatric patients or those taking diuretics, given the increased risk of dehydration and low blood pressure from severe diarrhea.
- Use with caution when combining with statins, since lomitapide increases statin blood levels and the risk of muscle toxicity, particularly with simvastatin.
- Use with caution in patients taking warfarin, since lomitapide increases warfarin levels and INR should be monitored more frequently after starting or adjusting lomitapide.
- Avoid grapefruit juice completely during treatment, since it inhibits the enzyme that breaks down lomitapide.
- Baseline imaging assessment of hepatic fibrosis, along with periodic laboratory markers of liver inflammation and fibrosis, should be carried out given the risk of hepatic fat accumulation.
Contraindications
- Contraindicated in patients with moderate or severe hepatic impairment, including those with unexplained persistent abnormal liver function tests.
- Contraindicated in patients with significant chronic bowel disease, such as inflammatory bowel disease or malabsorption.
- Contraindicated with concomitant use of more than 20 mg daily simvastatin (40 mg is allowed only if the patient has previously tolerated 80 mg daily for at least a year without muscle toxicity).
- Contraindicated with concomitant use of strong or moderate CYP3A4 inhibitors.
- Contraindicated during pregnancy.
- Contraindicated in patients with rare hereditary problems of galactose intolerance, Lapp-lactase deficiency, or glucose-galactose malabsorption.
- Contraindicated in patients with known hypersensitivity to lomitapide or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.
Drug interactions
- Strong and moderate CYP3A4 inhibitors, such as ketoconazole, clarithromycin, and itraconazole, are contraindicated, since they can increase lomitapide levels dramatically and raise the risk of toxicity.
- Weak CYP3A4 inhibitors, including atorvastatin, oral contraceptives, amiodarone, and cyclosporine among others, increase lomitapide exposure; doses should be separated by 12 hours or the lomitapide dose reduced.
- Lomitapide increases simvastatin exposure substantially, requiring a lower simvastatin dose to reduce the risk of muscle toxicity, including rhabdomyolysis.
- Lomitapide increases warfarin levels and INR, so more frequent INR monitoring is needed after starting lomitapide or changing its dose.
- Lomitapide is a P-glycoprotein inhibitor and may increase absorption of P-gp substrates such as digoxin, dabigatran, and colchicine, so dose reduction of these drugs should be considered.
- Bile acid sequestrants can interfere with lomitapide absorption, so dosing should be separated by at least 4 hours.
- Lomitapide has only a minor effect on atorvastatin, rosuvastatin, fenofibrate, ezetimibe, extended-release niacin, ethinyl estradiol, or norgestimate levels, so no dose adjustment is typically needed for these.
Food interactions
- Lomitapide should be taken without food, since taking it with food increases drug exposure and may worsen gastrointestinal side effects.
- Grapefruit juice must be avoided completely during treatment, since it moderately inhibits the enzyme responsible for breaking down lomitapide.
Time of administration
- Take lomitapide once daily in the evening with a glass of water, at least 2 hours after the evening meal.
Storage
- Store at 15°C to 30°C, with the container tightly closed and protected from moisture.
Patient take-away
- Lomitapide (JUXTAPID) is an add-on treatment for homozygous familial hypercholesterolemia, taken once daily without food alongside a strict low-fat diet, other cholesterol medications, and daily vitamin and fatty-acid supplements.
- The dose is increased gradually over several months to reduce stomach upset, and liver blood tests are checked regularly throughout treatment.
- Diarrhea, nausea, and stomach discomfort are common, especially early in treatment or with higher-fat meals; avoid grapefruit juice and limit alcohol.
- Tell your healthcare professional right away if you become pregnant, notice yellowing of the skin or eyes, or develop severe abdominal pain or unusual fatigue.